Island Pharmaceuticals

Island Pharmaceuticals is pleased to share a feature article on the company in The Australian, covering a wide range of topics - from the gap in the dengue fever treatment landscape, to the clinical progress of our lead drug, ISLA-101, and a new breed of mosquito that has brought dengue outbreaks to a new high this year.   The article highlights how ISLA-101 addresses a significant market gap, given there is currently no treatment for dengue fever and very limited vaccine options on the market. Currently in a Phase 2a/b clinical trial, both prophylactic (preventative) and therapeutic (treatment) properties of the drug candidate are being examined through human challenge studies, which ensures data readouts within weeks of dosing.   Thanks to tim boreham for this comprehensive article and for shedding light on the global challenges of dengue!    The full article can be accessed via this link: https://lnkd.in/gvfiPnz4 #dengue #mosquitobornedisease #antiviraltherapeutics

With ISLA-101, Island Pharmaceuticals is targeting a vast market opportunity in infectious disease treatment. Join us at the #TwilightInvestorBriefing to see how you can be part of advancing effective, life-saving treatments. Register now: bit.ly/TwilightNov2024   #DengueResearch #Biotech

In our October issue of #IslandWatch, we discuss the World Health Organization's report that a staggering 12.7 million dengue cases have been recorded this year so far – double the figure from 2023. Warm weather combined with humidity, and the rapid spread of tiger mosquitoes – a species that is more tolerant to urban and temperate settings, have intensified risks worldwide, even in our own country with the West Australian government issuing a mosquito-borne disease warning in October.   This issue also discusses Island Pharmaceuticals' key October milestones, including:  🔹 ISLA-101 clinical trial advances: Dosing of subjects in our Phase 2a/b trial, with data expected by year-end. 🔹 Funding boost: A$3.5 million raised to drive future milestones. 🔹 Annual General Meeting: Join us 19 Nov, 9 am (AEDT). 🔹 Releasing its Q1FY25 Activities Report, highlighting milestones including new board appointment of Chris Ntoumenopoulos and updates on Island’s various clinical programs.   Explore more insights and view the latest from dengue hotspots across the globe ➡️ https://lnkd.in/gGrM8BTD   #DengueAwareness #MosquitoBorneDiseases #GlobalHealth #ClinicalTrials #BiotechNews #ISLA101

Island Pharmaceuticals is pleased to share a report by The Australian on its activities for the September 2024 quarter, highlighting clinical progress for the Phase 2a/b PROTECT study in dengue disease, and the execution of a binding Letter of Intent for the potential acquisition of antiviral molecule galidesivir. This quarter saw changes for the Island board, followed by an announcement of a capital raise post-quarter.    Read the full report here: https://lnkd.in/gspwNifd   #biotechinvestment #ILA #dengue

Island Pharmaceuticals is pleased to release the September 2024 Quarterly Activity Report.   Island had an active first quarter of this financial year, achieving milestones including signing a binding Letter of Intent for the potential acquisition of antiviral molecule galidesivir, the appointment of Chris Ntoumenopoulos to the Island board as a Non-Executive Director, and clinical update of the Phase 2a/b PROTECT challenge study in dengue disease. These events are followed by significant post quarter activities, including the commencement of the ISLA-101 Phase 2a/b clinical trial and an A$3.5m Placement being secured to support Island’s clinical programs. Data readout of the Phase 2a cohort can be expected by the end of this calendar year.   Commenting on this quarter, Island CEO Dr David Foster said: “This quarter marked a breakthrough for Island. After submitting our amended protocol to the US FDA for ISLA-101, we were able to commence a Phase 2a/b trial, incorporating both prophylactic and therapeutic arms across two cohorts. We were delighted to welcome Chris Ntoumenopoulos to the Board this quarter. In his short time with the Company, Chris has proven to be a valuable asset, bringing fresh insights and a proactive approach that have positively influenced our direction and decision-making.”   Access the full Activities Report via this link: https://shorturl.at/lbFL5   #mosquitobornedisease #antiviraltherapeutics #ILA #biotech

A recent article in The Guardian highlights the unprecedented rise in dengue cases in 2024, doubling the cases in 2023 and making this year the largest outbreak in history.    Driven by climate change, urbanisation, and the emergence of tiger mosquitoes, a species that is more tolerant to urban settings and a wider range of temperatures, #dengue fever is spreading faster than ever and to more temperate regions where dengue is not traditionally endemic, increasing the urgency for new preventative and treatment options.    Read more about the scale of this challenge and why global action is critical: https://shorturl.at/mTZrP   #mosquitobornedisease #denguefever #antiviraltherapeutics David Foster

Island Pharmaceuticals’ Scientific Advisory Board member, Professor Stephen J. Thomas, MD from Upstate Global Health Institute (of Upstate Medical University) discusses the complexities of #dengue fever, and explains why effective #vaccine development has proven so difficult in this short video clip. This explanation underpins the potential opportunity for Island Pharmaceuticals with our dengue fever preventative and treatment candidate, ISLA-101.    Watch the full video interview here ➡️ https://shorturl.at/ANAb4

Island Pharmaceuticals is pleased to share a feature in the latest issue of #Bioshares.    The report highlights that ISLA-101, Island’s lead drug candidate in dengue fever, has gone through rigorous preclinical studies showing a demonstrated safety profile and promising efficacy. With the Phase 2a/b PROTECT study underway, Island is expecting data readout of the 2a prophylactic cohort as soon as the end of CY2024. The report also notes the high potential of #galidesivir as an antiviral drug candidate, which is currently being investigated under a due diligence program by Island.    Read the full report below or via this link: https://lnkd.in/guzr6P_g   #antiviraltherapeutics #drugrepurpose #dengue #mosquitobornedisease

The Australian reports that Island Pharmaceuticals is valued at 31 to 41 cents per share by Pitt Street Research in its recent report.   The report highlights Island’s advancing clinical progress and the low-risk profile of ISLA-101, Island’s lead drug candidate.    Read the full story here: https://lnkd.in/gs2ah2-n   #dengue #mosquitobornedisease #biotechinvestment

Island Pharmaceuticals is pleased to share an initiation report published by Pitt Street Research, noting a valuation range of A$0.31-$0.41 per share based on its analysis.   The report notes that Island has a company-defining 12 months ahead, and ISLA-101 is a substantially undervalued asset. As its Phase 2a/b PROTECT clinical trial of ISLA-101 in #dengue disease is well underway, data for the first prophylactic (preventative) cohort can be expected by the end of CY2024, with the second therapeutic cohort on track to commence in January 2025.   The report also highlights the #biodefense potential in galidesivir, a clinical-stage antiviral molecule that has shown clinical activities in more than 20 RNA viruses including Ebola and SARS-CoV-2. Island has executed a binding agreement that secures the exclusive right to #galidesivir for the next 12 months; an avid due diligence program is currently underway.   Thank you Stuart Roberts and Nicholas Sundich for this comprehensive analysis. The full report can be accessed via this link: https://lnkd.in/gUbSTYxq   #biotechinvestment #viraldiseases #antiviraltherapeutics David Foster Paul MacLeman